Edison Investment Research - Pharmaceutical & healthcare - NetScientific: NetScientific recently announced full-year results for 2017. It was a year of progress for the company, which is carrying forward into 2018. In February 2018, ProAxsis had its first commercial sale of Neutrophil Elastase Airways Test (NEATstik) for measuring active neutrophil elastase, in this case to a research lab conducting a respiratory clinical trial with a pharmaceutical company. In March, Vortex announced a collaboration with BioView for automated clinical biomarker identification of circulating tumour cells.
ISIN: GB00B9F4MT28
Original Article: NetScientific (NSCI) - Advancing on multiple fronts to commercialisation